In another facet of the tumor milieu, ARID1A's loss appears to recalibrate the immune landscape, evidenced by an influx of tumor‐infiltrating lymphocytes (TILs), notably CD8+ T cells, rendering the immune environment of such tumors more amenable to immunotherapy.239. This evidence concerns the gene CD8A and neoplasm.